Subsequent malignant neoplasms in pediatric patients initially diagnosed with neuroblastoma

Sara M. Federico, Heather B. Allewelt, Sheri L. Spunt, Melissa M. Hudson, Jianrong Wu, Catherine A. Billups, Jesse Jenkins, Victor M. Santana, Wayne L. Furman, Lisa McGregor

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

RESULTS: Twenty-one patients had a SMN. The 20- and 30-year cumulative incidences of a SMN were 2.6%±0.7% and 4.6%±1.1%, respectively. The standardized incidence ratio was 8.3 (95% confidence interval, 5.0-13.0). Five patients developed a SMN within 5 years from diagnosis. The median latency for the development of acute myeloid leukemia/myelodysplastic syndrome (n=4), sarcomas (n=7), and carcinomas (n=5) were 3.6, 9, and 24.2 years, respectively. Nine patients died from their SMN, including all with acute myeloid leukemia/myelodysplastic syndrome.

CONCLUSIONS: Patients with neuroblastoma have an increased risk of secondary neoplasia. Modification of risk-adapted therapies will likely alter the affected patient population and the incidence of SMNs. Future studies are necessary to link SMNs to treatment exposures and to evaluate the risk of SMNs beyond 30 years from diagnosis.

BACKGROUND: Most prior studies evaluating subsequent malignant neoplasms (SMNs) in patients with neuroblastoma are restricted to long-term survivors and/or their treatment exposures. This study investigates SMNs in patients diagnosed with neuroblastoma at our institution.

METHODS: Records of 646 patients treated for neuroblastoma at St Jude Children's Research Hospital between 1961 and 2005 were reviewed. Data from patients with SMNs were analyzed and the 20- and 30-year cumulative incidence of SMNs and standardized incidence ratio were calculated.

Original languageEnglish (US)
Pages (from-to)e6-e12
JournalJournal of Pediatric Hematology/Oncology
Volume37
Issue number1
DOIs
StatePublished - Jan 3 2015

Fingerprint

Neuroblastoma
Pediatrics
Neoplasms
Incidence
Myelodysplastic Syndromes
Acute Myeloid Leukemia
Sarcoma
Survivors
Therapeutics
Confidence Intervals
Carcinoma

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Cite this

Federico, Sara M. ; Allewelt, Heather B. ; Spunt, Sheri L. ; Hudson, Melissa M. ; Wu, Jianrong ; Billups, Catherine A. ; Jenkins, Jesse ; Santana, Victor M. ; Furman, Wayne L. ; McGregor, Lisa. / Subsequent malignant neoplasms in pediatric patients initially diagnosed with neuroblastoma. In: Journal of Pediatric Hematology/Oncology. 2015 ; Vol. 37, No. 1. pp. e6-e12.
@article{4b558089102646cf85e20c321b3084f0,
title = "Subsequent malignant neoplasms in pediatric patients initially diagnosed with neuroblastoma",
abstract = "RESULTS: Twenty-one patients had a SMN. The 20- and 30-year cumulative incidences of a SMN were 2.6{\%}±0.7{\%} and 4.6{\%}±1.1{\%}, respectively. The standardized incidence ratio was 8.3 (95{\%} confidence interval, 5.0-13.0). Five patients developed a SMN within 5 years from diagnosis. The median latency for the development of acute myeloid leukemia/myelodysplastic syndrome (n=4), sarcomas (n=7), and carcinomas (n=5) were 3.6, 9, and 24.2 years, respectively. Nine patients died from their SMN, including all with acute myeloid leukemia/myelodysplastic syndrome.CONCLUSIONS: Patients with neuroblastoma have an increased risk of secondary neoplasia. Modification of risk-adapted therapies will likely alter the affected patient population and the incidence of SMNs. Future studies are necessary to link SMNs to treatment exposures and to evaluate the risk of SMNs beyond 30 years from diagnosis.BACKGROUND: Most prior studies evaluating subsequent malignant neoplasms (SMNs) in patients with neuroblastoma are restricted to long-term survivors and/or their treatment exposures. This study investigates SMNs in patients diagnosed with neuroblastoma at our institution.METHODS: Records of 646 patients treated for neuroblastoma at St Jude Children's Research Hospital between 1961 and 2005 were reviewed. Data from patients with SMNs were analyzed and the 20- and 30-year cumulative incidence of SMNs and standardized incidence ratio were calculated.",
author = "Federico, {Sara M.} and Allewelt, {Heather B.} and Spunt, {Sheri L.} and Hudson, {Melissa M.} and Jianrong Wu and Billups, {Catherine A.} and Jesse Jenkins and Santana, {Victor M.} and Furman, {Wayne L.} and Lisa McGregor",
year = "2015",
month = "1",
day = "3",
doi = "10.1097/MPH.0000000000000148",
language = "English (US)",
volume = "37",
pages = "e6--e12",
journal = "Journal of Pediatric Hematology/Oncology",
issn = "1077-4114",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

Federico, SM, Allewelt, HB, Spunt, SL, Hudson, MM, Wu, J, Billups, CA, Jenkins, J, Santana, VM, Furman, WL & McGregor, L 2015, 'Subsequent malignant neoplasms in pediatric patients initially diagnosed with neuroblastoma', Journal of Pediatric Hematology/Oncology, vol. 37, no. 1, pp. e6-e12. https://doi.org/10.1097/MPH.0000000000000148

Subsequent malignant neoplasms in pediatric patients initially diagnosed with neuroblastoma. / Federico, Sara M.; Allewelt, Heather B.; Spunt, Sheri L.; Hudson, Melissa M.; Wu, Jianrong; Billups, Catherine A.; Jenkins, Jesse; Santana, Victor M.; Furman, Wayne L.; McGregor, Lisa.

In: Journal of Pediatric Hematology/Oncology, Vol. 37, No. 1, 03.01.2015, p. e6-e12.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Subsequent malignant neoplasms in pediatric patients initially diagnosed with neuroblastoma

AU - Federico, Sara M.

AU - Allewelt, Heather B.

AU - Spunt, Sheri L.

AU - Hudson, Melissa M.

AU - Wu, Jianrong

AU - Billups, Catherine A.

AU - Jenkins, Jesse

AU - Santana, Victor M.

AU - Furman, Wayne L.

AU - McGregor, Lisa

PY - 2015/1/3

Y1 - 2015/1/3

N2 - RESULTS: Twenty-one patients had a SMN. The 20- and 30-year cumulative incidences of a SMN were 2.6%±0.7% and 4.6%±1.1%, respectively. The standardized incidence ratio was 8.3 (95% confidence interval, 5.0-13.0). Five patients developed a SMN within 5 years from diagnosis. The median latency for the development of acute myeloid leukemia/myelodysplastic syndrome (n=4), sarcomas (n=7), and carcinomas (n=5) were 3.6, 9, and 24.2 years, respectively. Nine patients died from their SMN, including all with acute myeloid leukemia/myelodysplastic syndrome.CONCLUSIONS: Patients with neuroblastoma have an increased risk of secondary neoplasia. Modification of risk-adapted therapies will likely alter the affected patient population and the incidence of SMNs. Future studies are necessary to link SMNs to treatment exposures and to evaluate the risk of SMNs beyond 30 years from diagnosis.BACKGROUND: Most prior studies evaluating subsequent malignant neoplasms (SMNs) in patients with neuroblastoma are restricted to long-term survivors and/or their treatment exposures. This study investigates SMNs in patients diagnosed with neuroblastoma at our institution.METHODS: Records of 646 patients treated for neuroblastoma at St Jude Children's Research Hospital between 1961 and 2005 were reviewed. Data from patients with SMNs were analyzed and the 20- and 30-year cumulative incidence of SMNs and standardized incidence ratio were calculated.

AB - RESULTS: Twenty-one patients had a SMN. The 20- and 30-year cumulative incidences of a SMN were 2.6%±0.7% and 4.6%±1.1%, respectively. The standardized incidence ratio was 8.3 (95% confidence interval, 5.0-13.0). Five patients developed a SMN within 5 years from diagnosis. The median latency for the development of acute myeloid leukemia/myelodysplastic syndrome (n=4), sarcomas (n=7), and carcinomas (n=5) were 3.6, 9, and 24.2 years, respectively. Nine patients died from their SMN, including all with acute myeloid leukemia/myelodysplastic syndrome.CONCLUSIONS: Patients with neuroblastoma have an increased risk of secondary neoplasia. Modification of risk-adapted therapies will likely alter the affected patient population and the incidence of SMNs. Future studies are necessary to link SMNs to treatment exposures and to evaluate the risk of SMNs beyond 30 years from diagnosis.BACKGROUND: Most prior studies evaluating subsequent malignant neoplasms (SMNs) in patients with neuroblastoma are restricted to long-term survivors and/or their treatment exposures. This study investigates SMNs in patients diagnosed with neuroblastoma at our institution.METHODS: Records of 646 patients treated for neuroblastoma at St Jude Children's Research Hospital between 1961 and 2005 were reviewed. Data from patients with SMNs were analyzed and the 20- and 30-year cumulative incidence of SMNs and standardized incidence ratio were calculated.

UR - http://www.scopus.com/inward/record.url?scp=84920589556&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920589556&partnerID=8YFLogxK

U2 - 10.1097/MPH.0000000000000148

DO - 10.1097/MPH.0000000000000148

M3 - Article

VL - 37

SP - e6-e12

JO - Journal of Pediatric Hematology/Oncology

JF - Journal of Pediatric Hematology/Oncology

SN - 1077-4114

IS - 1

ER -